The incidence of neuropsychiatric disorders has increased dramatically over the past decades, necessitating continued efforts to identify drugs that will be safer and more efficacious than currently prescribed medications for conditions like depression.
Neuroplasticity is known to play a crucial role in the onset and progression of symptoms in a variety of psychiatric disorders. This relationship provides a handle for continued drug discovery to identify novel targets and molecules that affect neuroplasticity in vitro. However, quantification of neuroplasticity effects has been challenging due to low throughput and assay variability.
In this webcast, you will learn about a suite of native in vitro models developed by Cellectricon to study neuroplasticity. These highly-consistent models are capable of quantifying structural and functional changes at a scale required for drug discovery. Case studies will demonstrate how the assays can be applied for screening of novel drugs and for elucidating mechanisms of action.
Learn how to:
• Address challenges of low throughput and high variability for neuroplasticity research
• Apply neuroplasticity in vitro models to prioritize molecules in the drug discovery process
• Combine techniques such as optical electrophysiology and high content imaging to investigate neurobiological events from neuritogenesis to synaptogenesis and synaptic function
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Cellectricon, who retails sole responsibility for content. About this content.
Speakers
Paul Karila, Head of Drug Discovery, Cellectricon AB
Paul Karila, PhD, joined Cellectricon in 2012 as head of the company’s Discovery Services. He previously held leadership positions at the Departments of Molecular Pharmacology and Neuroscience at AstraZeneca. Paul earned his PhD in animal physiology from University of Gothenburg, Sweden, and was a Postdoctoral Fellow at University of Pittsburgh School of Medicine, USA.
Susanne Lardell, External Collaborations Manager, Cellectricon AB
Susanne joined Cellectricon in 2012 as External Collaborations Manager and Senior Scientist. Prior to joining Cellectricon, she was a Senior Research Scientist at AstraZeneca working in the department of Drug metabolism and Pharmacokinetics. Susanne has a MSc in Pharmaceutical Bioscience from University of Gothenburg, Sweden.
Moderator
Sarah Hiddleston, Nature Research Custom Media
Sarah Hiddleston is a freelance journalist who has worked with Nature Research Custom Media since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.
